Carboplatin, 5-FU, and Cetuximab Treatment Regimen for Head and Neck Cancer

The carboplatin + 5-FU + cetuximab regimen for head and neck cancer is a systemic treatment protocol used particularly in recurrent or metastatic squamous cell carcinoma when cisplatin cannot be given.

Carboplatin is a platinum-derived alkylating chemotherapy drug. It covalently binds guanine bases in DNA, forming intrastrand and interstrand cross-links. These disrupt DNA replication and transcription, causing cell-cycle arrest at the G2-M phase and apoptosis (programmed cell death). Carboplatin is particularly effective against rapidly proliferating tumor cells. It is less nephrotoxic and emetogenic than cisplatin but has more pronounced myelosuppressive effects.

5-Fluorouracil (5-FU) is an antimetabolite chemotherapy agent and pyrimidine analog. It is converted into active metabolites inside the cell and acts through two main mechanisms:

• 5-FU irreversibly inhibits thymidylate synthase (TS), preventing formation of thymidylate (dTMP), which is needed for DNA synthesis. This halts DNA synthesis and causes cell death.
• It is also incorporated into RNA, disrupting mRNA synthesis and affecting protein synthesis.

This dual mechanism produces marked cytotoxicity, particularly in rapidly dividing cells.

Cetuximab (Cetuximab) is a recombinant, chimeric (human–monkey-derived) monoclonal antibody binding the epidermal growth factor receptor (EGFR). EGFR is a membrane receptor with tyrosine kinase activity involved in cell growth, proliferation, angiogenesis, and metastasis. Cetuximab binds the ligand-binding region of EGFR, preventing receptor activation and inhibiting downstream MAPK, PI3K/AKT, and JAK/STAT signaling. This suppresses tumor cell proliferation, angiogenesis, and metastatic potential. It also promotes apoptosis. It has been effective in head and neck tumors with high EGFR expression.

Together, carboplatin and 5-FU directly disrupt DNA and RNA synthesis and trigger cell death, while cetuximab interrupts extracellular signaling to stop tumor growth and spread. The combination enhances treatment response through synergy.

Treatment Goals

• Suppressing Tumor Cell Proliferation: inhibiting EGFR signaling with cetuximab reduces cell proliferation, angiogenesis, and metastatic capacity.
• Triggering Cell Death by Disrupting DNA and RNA Synthesis: carboplatin and 5-FU induce apoptosis (programmed cell death) through DNA cross-linking and thymidylate synthase inhibition.
• Reducing Tumor Burden (Cytoreduction): cytotoxic drugs shrink local and systemic tumor masses, providing symptom relief.
• Stabilizing Disease and Delaying Progression: combination therapy provides higher response rates and longer progression-free survival (PFS) than single agents.
• Preserving Quality of Life and Functional Capacity: tumor control aims particularly to prevent impairment of functions such as speech and swallowing.
• Providing an Alternative for Unsuitable Patients: offers a more tolerable chemotherapy option for patients with cisplatin contraindications, limited kidney function, or older age.

Treatment Indication

Diagnosis:

• recurrent or metastatic squamous cell carcinoma of the head and neck
• particularly primary tumors of the oral cavity, oropharynx, hypopharynx, or larynx

Patients Previously Treated with Radiotherapy or Surgery:

• local or distant recurrence despite curative surgery and/or radiotherapy
• given as systemic treatment in these patients.

No Previous Cetuximab Use:

• recommended if cetuximab is being given for the first time in this protocol.
• It can also be an alternative after progression on pembrolizumab monotherapy.

Patients with Cisplatin Contraindications:

• carboplatin is preferred when cisplatin cannot be given because of renal failure, older age, hearing loss, cardiac dysfunction, or similar reasons.
• It became a standard alternative for this group after the EXTREME study.

Performance Status:

• patients with a World Health Organization (WHO) Performance Score of 0–1
• meaning physically active patients able to maintain daily life

EGFR-Expressing Tumors:

• cetuximab is effective in EGFR-expressing tumors (routine testing is not required, but high expression is associated with a better response)

In essence, carboplatin + 5-FU + cetuximab is indicated in the following situation:

"Recommended first line in patients with locally advanced or metastatic head and neck squamous cell cancer who have not previously received cetuximab, cannot receive cisplatin, have WHO PS 0–1, and have EGFR expression."

Situations Unsuitable for Treatment

Poor Performance Status (WHO PS ≥ 2)

• Not recommended in patients with severely restricted physical activity, bed dependence, or difficulty with self-care.
• These patients have low toxicity tolerance and limited treatment benefit.

Patients Previously Treated with Cetuximab

• Repeat treatment is not recommended if cetuximab resistance or a previous serious reaction has occurred.

Patients Able and Suitable to Receive Cisplatin

• This protocol is primarily for patients with cisplatin contraindications. If cisplatin can be given, the EXTREME protocol is preferred directly.

Severe Renal Failure (CrCl < 20 mL/min)

• If carboplatin dosing cannot be calculated safely, 5-FU clearance is reduced; there is a risk of severe toxicity.

Severe Liver Failure

• AST/ALT > 3.5 x ULN and/or alkaline phosphatase > 6 x ULN impairs 5-FU metabolism and increases toxicity.
• If bilirubin > 3 mg/dL, caution is also needed with cetuximab and carboplatin.

Dihydropyrimidine Dehydrogenase (DPD) Deficiency

• A genetic deficiency of DPD (DPYD mutation), the enzyme involved in 5-FU metabolism, carries a risk of severe and fatal toxicity.
• 5-FU should not be used in these patients.

History of Severe Allergy or Anaphylaxis (Particularly to Cetuximab)

• Reuse is contraindicated after a previous ≥ Grade 3 infusion reaction to cetuximab.
• Resuscitation equipment is required; avoid treatment if allergy risk is high.

Active Infection or Uncontrolled Comorbidity

• Treatment may cause severe complications in conditions such as febrile neutropenia, sepsis, active pneumonia, or uncontrolled heart disease.
• Chemotherapy should not begin before stabilization.

Interstitial Lung Disease or Pulmonary Fibrosis

• Cetuximab may rarely cause interstitial lung disease and worsen existing lung pathology.

Pregnancy and Breastfeeding

• Carboplatin, 5-FU, and cetuximab are all fetotoxic and teratogenic.
• Treatment is contraindicated in breastfeeding mothers.

SGK Reimbursement Status

Carboplatin and 5-FU:

• these two chemotherapy drugs are generally reimbursed by SGK.
• They can be prescribed with appropriate indications and e-prescription approval.

Cetuximab (Erbitux):

• SGK reimburses cetuximab only when the following specific criteria are met:
• Locally advanced, recurrent, or metastatic squamous cell carcinoma of the head and neck
• Given either concurrently with radiotherapy,
• Or combined with chemotherapy (carboplatin + 5-FU)
• No previous cetuximab use
• Histopathological EGFR expression (although unclear in SGK reimbursement conditions, some hospitals may request testing)
• WHO performance status 0–1
• An institution-approved medical board report is required.
• The report must be signed by an oncologist, internist, and radiology/surgery specialist
• ICD-10 code: C00–C14 (oral cavity, pharynx, larynx, etc.)
• The report must specify the treatment protocol and dose.

Dosing Schedule

This protocol is planned in 21-day cycles, with a maximum of 6 cycles. On the first day, a loading dose of cetuximab, a single carboplatin dose, and continuous 5-FU infusion are started. Only 5-FU continues on subsequent days. In responders, cetuximab maintenance continues every two weeks after 6 cycles.

Before treatment, recommended premedications to prevent infusion reactions and cetuximab-related allergic events are given approximately 30 minutes beforehand. They are:

• Chlorpheniramine 10 mg IV (antihistamine)
• Dexamethasone 8 mg IV (steroid)
• Ranitidine 150 mg PO/PEG (H2 receptor antagonist)
• Paracetamol 1000 mg PO/PEG (antipyretic and analgesic)

Day 1 (Treatment Start):

Cetuximab (Loading Dose):

• Dose: 400 mg/m²
• Administration: IV infusion over 120 minutes
• Maximum infusion rate: 5 mg/min
• Observe patients during infusion and for 1 hour afterward (assess temperature, blood pressure, pulse, and breathing)

Carboplatin:

• Dose: AUC 5, calculated using the Calvert formula
• Formula: Dose (mg) = AUC × (GFR + 25)
• Administration: IV infusion over 30–60 minutes in 250–500 mL of 5% dextrose solution
• Start at least 1 hour after the cetuximab infusion has finished.

5-Fluorouracil (5-FU):

• Dose: 1000 mg/m²/day, continuous IV infusion
• Duration: 96 hours (4 days), continuously through an infusion pump.
• Alternatively, a daily infusion over 22 hours in 1000 mL of 0.9% NaCl may be preferred.

Days 2–4:

• Continuous IV 5-FU infusion continues.
• No new administration is needed each day; the infusion pump is loaded once.

Days 8 and 15 (and 1, 8, 15 in subsequent cycles):

Cetuximab maintenance dose:

• Dose: 250 mg/m²
• Administration: IV infusion over 60 minutes
• Maximum infusion rate: 10 mg/min

Alternatively, maintenance cetuximab may be given at 500 mg/m² every two weeks (off-label, but preferred at some centers).

Points Requiring Attention

Serious Infusion Reactions (Cetuximab-Related)

• As an EGFR monoclonal antibody, cetuximab may cause anaphylaxis and infusion reactions resembling cytokine release syndrome.
• Reactions generally occur during the first infusion.
• Keep resuscitation equipment available and always premedicate with an antihistamine, steroid, and paracetamol before infusion.
• Permanently discontinue cetuximab if a ≥ Grade 3 infusion reaction develops.

Dihydropyrimidine Dehydrogenase (DPD) Deficiency

• 5-FU is metabolized by DPD. Genetic deficiency of this enzyme may cause fatal toxicity (severe neutropenia, mucositis, diarrhea).
• Testing for DPYD mutations is recommended.
• If deficiency is found, 5-FU should not be given or its dose should be substantially reduced.

Hypomagnesemia and Electrolyte Disorders

• Cetuximab may cause magnesium loss through the renal tubules.
• Monitor serum magnesium, potassium, and calcium regularly; if Mg < 0.6 mmol/L, replace it with IV magnesium sulfate.
• Oral supplementation may also be needed with prolonged use.

Oral and Gastrointestinal Toxicities

• 5-FU-related stomatitis, mucositis, and diarrhea are common.
• If ≥ Grade 2 mucositis or diarrhea develops, withhold 5-FU and plan a dose reduction.
• Delay treatment until toxicity falls to Grade 1 or below.
• Keep oral care protocols and supportive treatments such as loperamide available.

Skin Toxicities (Cetuximab-Related Acneiform Rash)

• EGFR inhibition may cause acneiform rash on the face, trunk, or scalp.
• Doxycycline (100 mg/day) prophylaxis is recommended. If the reaction is ≥ Grade 2, treatment may be interrupted and dose reduction planned.
• Sun protection is recommended (photosensitivity risk).

Myelosuppression Risk (Particularly Carboplatin and 5-FU)

• Neutropenia, thrombocytopenia, and anemia may develop.
• Delay treatment if neutrophils < 1.5 x 10⁹/L or platelets < 100 x 10⁹/L.
• If hematological toxicity recurs, reduce carboplatin to AUC 4 and continue 5-FU at 80% of the dose.

Cardiotoxicity (5-FU-Related)

• 5-FU may rarely cause coronary vasospasm, arrhythmia, and ischemic syndromes.
• Particular caution is needed with a history of coronary artery disease.
• Stop 5-FU immediately if chest pain or ECG changes develop.

Nephrotoxicity and Dose Adjustment (Carboplatin)

• Carboplatin is eliminated through the kidneys. Calculate dosing carefully with reduced GFR; do not give it if CrCl < 20 mL/min.
• Monitor renal function regularly throughout treatment.

Serious Comorbidity or Frailty

• Older age, poor performance status (≥ WHO PS 2), malnutrition, or polypharmacy increase the risk of excessive toxicity from this combination.
• Single-agent immunotherapy or supportive care should be preferred in such patients.

Drug-Specific Interactions

• Concurrent folic acid/folinic acid increases 5-FU toxicity.
• Carboplatin with aminoglycosides or diuretics increases nephrotoxicity and ototoxicity risk.
• Carboplatin may reduce phenytoin absorption (potentially reducing anticonvulsant efficacy).

Adverse Effects

The most common adverse effects reported in clinical trials of carboplatin + fluorouracil + cetuximab are listed below. These percentages reflect only the proportions of patients experiencing serious or life-threatening adverse effects:

• Low white blood cells (leukopenia): 22%
• Low red blood cells (anemia): 13%
• Low platelet count (thrombocytopenia): 11%
• Skin reaction: 9%
• Low potassium (hypokalemia): 7%
• Vomiting: 5%
• Fatigue or weakness: 5%
• Loss of appetite: 5%
• Low magnesium (hypomagnesemia): 5%
• Neutropenic fever: 5%
• Shortness of breath (dyspnea): 4%
• Pneumonia: 4%
• Low calcium (hypocalcemia): 4%
• Heart attack (myocardial infarction): 3%
• Heart failure: 2%